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Abstract Gonadotropin-releasing hormone-I (GnRH-I), pre-
sent in the mammalian hypothalamus, regulates reproduction. In
this study we demonstrate, for the first time, that an additional
isoform of GnRH, [His5, Trp7, Tyr8] GnRH-I (GnRH-II) is
present in the brain of the mouse, rat and human. Human and rat
brain extracts contain two isoforms of GnRH, GnRH-I and
GnRH-II, which exhibited identical chromatographic properties
to the respective synthetic peptides, in high performance liquid
chromatography. Using immunohistochemical techniques we
have found that GnRH-II is present in neuronal cells that are
localized mainly in the periaqueductal area as well as in the
oculomotor and red nuclei of the midbrain. It is of interest to note
that in the hypogonadal mouse, although the GnRH-I gene is
deleted, GnRH-II is present. Substantial concentrations of
GnRH-II are also present in the hypothalamus and stored in
the human pituitary stalk or in the mouse median eminence. By
using reverse transcription (RT)-PCR we have also found that
while GnRH-II is not expressed in the cerebellum, it is expressed
in all three structures of the brain stem: midbrain, pons and
medulla oblongata.
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1. Introduction
Gonadotropin-releasing hormone-I (GnRH-I), (pGlu-His-
Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2), originally isolated
from the mammalian hypothalamus plays a pivotal role as
the physiologic regulator of reproduction [1,2]. This peptide
is synthesized by hypothalamic neurosecretory cells and upon
release it reaches the pituitary gland, by way of a specialized
portal system, to induce the synthesis and secretion of the
gonadotropic hormones which regulate gonadal functions.
Today, a dozen isoforms of GnRH are known in vertebrates,
all are decapeptides that are conserved by 10^50% as com-
pared to GnRH-I [3]. It can be stated, in general, that at least
two di¡erent isoforms of GnRH are expressed in the brain of
each of the lower vertebrate species [4]. One isoform, [His5,
Trp7, Tyr8] GnRH-I, named GnRH-II, originally isolated
from chicken brain [5] is expressed in almost all vertebrate
classes. GnRH-II, the most ancient and conserved form of
GnRH has been found in cartilage and bony ¢sh [6^9], am-
phibians [10^12], reptiles [13,14], birds [5,15], and metatherian
species [16]. In the placental species of mammals, only GnRH-
I has been detected [17], although recently GnRH-II was re-
vealed in early evolved eutherian species such as the musk
shrew and mole, of the insectivora order [16,18]. The form
of GnRH which varies across vertebrate classes, is localized
mainly in the hypothalamus and is responsible for the regu-
lation of reproduction [19], whereas GnRH-II is localized
mainly in extrahypothalamic brain areas, mostly in the mid-
brain [20,21]. Thus GnRH-II is an ancient isoform of GnRH
and is structurally conserved for over 500 million years of
evolution, suggesting that its neuronal functions are of utmost
importance.
Recently it was reported that in the rhesus monkey immu-
noreactive GnRH-II neurons are scattered in the periaqueduc-
tal region of the midbrain, with a few positive cells in the
basal hypothalamus [22]. However, GnRH-II positive cells
could not be detected in the brain of several rodents [22]. It
was also reported that a gene, encoding GnRH-II, is ex-
pressed in the human brain [23]. However, GnRH-II gene
expression in the brain stem structures was not measured,
nor the presence of the GnRH-II peptide in the human brain.
By using high performance liquid chromatography (HPLC),
immunocytochemistry, radioimmunoassay (RIA), and molec-
ular biology techniques, we could demonstrate the presence of
GnRH-II in the brain of the mouse, rat and human.
2. Materials and methods
2.1. Tissue processing for GnRH determination
All animal experiments were carried out in compliance with the
regulations of the Weizmann Institute of Science. The brains of 50
female rats, 25 days old, were removed immediately after killing,
immersed in ice-cold 0.1 N HCl and homogenized by a Te£on-glass
homogenizer. Following centrifugation (12 000Ug, 30 min at 4‡C) the
supernatant was pumped onto columns of Sep-Pak C-18 cartridges,
eluted by methanol and evaporated by nitrogen. Speci¢c regions of a
human brain were received during a routine autopsy at Rabin Medical
Center from a 77-years-old man who died of pyonephrosis. The body
was kept for 38 h at 4‡C until autopsy. Samples from some of these
regions were extracted for total RNA and the rest was homogenized
in 0.1 N HCl and processed as described for the rat brain. The brain
extracts were processed through reversed phase (RP) HPLC using C-
18 columns, and eluted using the following conditions: eluent A, 0.1%
tri£uoroacetic acid in water; eluent B, 75% CH3CN in 0.1% tri£uoro-
acetic acid. The gradient program consisted of a linear gradient of
eluent B 20^30% for 5 min at a £ow rate of 1 ml/min, followed by
isocratic elution of 30% eluent B for 35 min, and continued with 100%
of eluent B for additional 20 min. The fractions were evaporated to a
volume of 0.2 ml and reconstituted with 0.1 M of phosphate bu¡er
(PB, pH 7.4) containing 0.1% of bovine Q-globulin. All fractions were
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assayed for GnRH-I and GnRH-II concentration by RIA using the
appropriate antisera. The elution positions of the synthetic peptides
were determined by application of 1 Wg of GnRH-I and of GnRH-II
(Phoenix Pharmaceuticals, Mountain View, CA; catalog no. 040-02
and 040-01, respectively; 99% purity by HPLC analysis). After thor-
ough washing, a blank run was monitored by RIA to ensure that the
column was not contaminated.
2.2. Radioiodination and radioimmunoassay
Iodination of synthetic GnRH-I or GnRH-II was carried out by
using the chloramine-T method [24]. Free iodine was removed on a
Sep-Pak C-18 cartridge and the 125I labeled peptides were separated
from the unlabeled peptides by HPLC. GnRH concentrations in sam-
ples of brain extracts were determined by RIA as previously described
[25].
2.3. Antibodies
The following antisera were used throughout this study: a polyclo-
nal antibody against GnRH-I, prepared and characterized in our lab-
oratory, was used for RIA [25]. GnRH-II did not displace any of the
bound 125I-GnRH-I even at a concentration that exceeded by 1000
times the GnRH-I concentration that is needed for displacing 50% of
the tracer (20 ng vs. 20 pg). A monoclonal antibody against GnRH-I,
kindly provided by Dr. H.F. Urbansky, was used at dilutions ranging
from 1:4000 to 1:10 000 for the immuno£uorescence studies; the spe-
ci¢city of this antibody (HU4H) was reported elsewhere [26]. A poly-
clonal antibody against GnRH-II (aCII6) was kindly provided by Dr.
K. Okuzawa and its speci¢city was previously de¢ned [27]. Additional
speci¢city tests in our laboratory demonstrated that GnRH-I did not
displace any of the bound 125I-GnRH-II, even at a concentration that
exceeded 2500 times the GnRH-II concentration that is needed to
displace 50% of the tracer (20 ng vs. 8 pg). We have utilized dilutions
ranging from 1:4000 to 1:10 000 of this antibody for the immunohis-
tochemical studies.
2.4. Immunohistochemical procedure
The localization of GnRH-II in the midbrain of mouse, rat and
human, was carried out by application of a speci¢c antibody to the
brain slices followed by a biotinylated secondary antibody, and of an
avidine-biotin-horseradish peroxidase complex according to the pro-
cedures described by Eilam et al. [28]. Human brain samples were
obtained during routine autopsies at Rabin Medical Center from a
36-weeks-old male infant who died of bilateral polycystic kidneys and
from a 60-years-old man who died of pulmonary edema. The bodies
were kept 8 h at 4‡C until autopsy. The brain samples were ¢xed in
10% neutral bu¡ered formalin, embedded in para⁄n and cut into 6 Wm
thick sections. Ten-weeks-old female and male rats or mice were
also used. The animals were deeply anesthetized with 10% chloral
hydrate (2.5 ml/animal) and perfused through the left ventricle of
the heart, with 0.1 M phosphate bu¡ered saline (PBS), followed by
4% paraformaldehyde in 0.1 M PBS and 4% sucrose. The brains were
removed and immersed in a post-¢xation solution (1% paraformalde-
hyde, 30% sucrose in 0.1 M PBS, pH 7.4) for at least one week.
Frozen brains were cut by microtome, and sections (32 Wm) were
collected in a solution of 0.1 M PBS containing 0.1% sodium-azid,
washed three times with PBS 0.1 M and incubated for 15 min in 0.3%
hydrogen peroxide to reduce endogenous peroxidase activity. After an
additional wash, the sections were incubated for 2 h in a blocking
medium containing 20% normal goat serum and 0.5% Triton X-100.
The sections were incubated over-night at 4‡C with antisera to
GnRH-II or GnRH-I, rinsed well and incubated with an avidin-bio-
tin-peroxidase complex (ABC Vectastain, Vector Laboratories, Bur-
lingame, CA) followed by nickel-intensi¢ed diaminobenzidine with
hydrogen peroxide as the chromogen. In order to determine the spe-
ci¢city of the signals we have included several control groups in which
the antibodies were preabsorbed with excess (100 Wg) of GnRH-I or
GnRH-II for 24 h. Additional control sections were incubated with-
out the ¢rst antibody or with an antibody against vasopressin that is
known to be expressed only in the paraventricular nucleus of the
hypothalamus. Additional sections were stained by cresyl violet to
con¢rm the neuroanatomical location of immunoreactivity.
2.5. Double £uorescence immunocytochemical analysis
Sections of the hpg mouse hypothalamus obtained from perfused
brains of 3-months-old male were analyzed by double £uorescence
immunocytochemistry using £uorescence microscopy, according to
the procedure described by Kim et al. [29]. The slices were washed
(5 minU3) with PB and were permeabilized for 3 min with 0.5%
Triton X-100, followed by three washes with PB. The slices were
then incubated with 1% of bovine serum albumin (200 Wl) in PB
for 1 h at room temperature followed by the addition of the
primary antibodies for 12^15 h at 4‡C. The slices were then washed
(5 minU3) with 0.1 M PB, and incubated for 2 h at room temperature
with either £uorescein or rhodamine-conjugated secondary antibody
as follows: goat anti-mouse conjugated to Cy2 (green £uorescence,
Jackson, Immunoreaserch), goat anti-rabbit conjugated to rhodamin
(red £uorescence, Jackson, Immunoreaserch), or both. Fluorescence
was visualized by £uorescence microscopy using green and red ¢lters
for GnRH-I and GnRH-II, respectively.
2.6. Reversed transcription (RT)-PCR and Southern analysis
Total RNA was extracted by using Trizol RNA isolation reagent
(Molecular Research Center, Cincinnati, OH) according to the proto-
col of the manufacturer. We have used RT-PCR [30] to amplify the
levels of endogenous GnRH-II mRNA that may be present in the
human midbrain, pons, medulla oblongata and cerebellum samples,
using oligonucleotide primers that were described by White et al. [23].
The expression of the ribosomal protein S-14 [31], derived from the
same tissue preparations, served as a control. Ampli¢cation was car-
ried out for 31 cycles, the annealing temperature was decreased from
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Fig. 1. RP HPLC elution pro¢le of GnRH-I and GnRH-II ex-
tracted from rat brain (A) and from human midbrain (B). Fractions
(1 ml) of the eluate were collected, evaporated and reconstituted.
All fractions were assayed for GnRH-I and for GnRH-II by RIA,
using speci¢c antibodies for either GnRH-I (open columns) or
GnRH-II (solid columns). The elution position of synthetic GnRH-I
(I) or GnRH-II (II) is indicated by black arrows.
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65 to 60‡C and the ¢nal MgCl2 concentration was 2.5 mM. The PCR
products were transferred to a nylon membrane (Hybond-N+, Amer-
sham) in 20USSC solution for over-night and was baked in a vacuum
oven at 80‡C for 2 h. Pre-hybridization was performed in the presence
of 6USSC, 5UDenhart’s solution, 5 mM EDTA and 0.2 mg/ml sal-
mon sperm DNA for 3 h at 60‡C. Over-night hybridization was per-
formed at 64‡C, in the presence of a 32P labeled probe, speci¢c to the
GnRH-II that was described by White et al. [23] and exposed for 1 h
using a phosphorimager (445SI, Molecular Dynamics).
3. Results
Acid extracts of whole rat brain or of speci¢c regions of the
human brain were eluted through RP C-18 columns on HPLC
using an isocratic elution program, that separates synthetic
GnRH-I from GnRH-II (Fig. 1, black arrows). The concen-
tration of GnRH-I or GnRH-II in the eluate of the brain
extracts was determined by RIA using speci¢c antibodies to
either GnRH-I or GnRH-II. Fig. 1 demonstrates that the
elution pro¢les of the immunoreactive neuropeptides that
were extracted from the brain were identical to those of the
synthetic peptides. These results prove the existence of
GnRH-II in the rat brain (Fig. 1A) and human midbrain
(Fig. 1B). The total concentration of GnRH-II in the rat brain
was found to be 15^20% of that of GnRH-I. The concentra-
tion of GnRH-II in the various regions of the human brain
has to be regarded only qualitatively since they represent data
obtained from a single brain of a 77-years-old person. Never-
theless, the highest amounts of GnRH-II were found in the
midbrain region and in the pituitary stalk (1.2 ng, each), lower
concentrations were found in the hypothalamus (0.36 ng),
medulla oblongata (22 pg) and in the pons (18 pg). GnRH-
II was undetectable in 1 g tissue samples taken from the
frontal cortex or cerebellum. The presence of GnRH-II in
the hypothalamus suggests that in addition to its possible
role as a neurotransmitter in the brain, it may be also active
as a neurohormone in the pituitary gland.
The localization of GnRH-II in the midbrain of mouse, rat
and human, was carried out by application of a speci¢c anti-
body followed by biotinylated secondary antibody, and of an
avidine-biotin-horseradish peroxidase complex. Fig. 2 demon-
strates immunoreactive neurons in the midbrain region of the
mouse, rat and human. Numerous immunoreactive GnRH-II
neurons are found in the oculomotor nucleus of the rat mid-
brain (Fig. 2A^C) and to a lesser extent in the red nucleus
(Fig. 2A). A similar distribution pattern of GnRH-II positive
cells is also evident in the mouse (data not shown). It is well
established that GnRH-I is not produced by the hypogonadal
mouse due to a deletion in the GnRH-I gene [32,33]. We have
therefore looked for immunopositive GnRH-II cells in the
brain of the hypogonadal mouse. Indeed, we have found a
similar distribution of GnRH-II immunoreactive neurons in
the brain of the mutant mouse as compared to the normal
mouse. GnRH-II neurons are concentrated in the oculomotor
nucleus (Fig. 2D) and in the arcuate nucleus of the hypothal-
amus (Fig. 2E) of the hypogonadal mouse. Further studies on
the hpg mouse brain were carried out using double £uores-
cence microscopy (Fig. 3). Slices of the hypothalamic region
were reacted with a monoclonal antibody against GnRH-I
and a polyclonal antibody against GnRH-II. GnRH-II immu-
noreactivity is clearly observed in the arcuate nucleus region
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Fig. 3. Double £uorescence microscopy of the hypothalamic region
of the hpg male mouse. GnRH-I monoclonal antibody was reacted
with goat anti-mouse Cy2, whereas GnRH-II polyclonal antibody
was reacted with goat anti-rabbit rhodamin. Immunoreactive cells
(arrows), in the area of the arcuate nucleus of the hypothalamus,
were observed only with the red ¢lter (antibody against GnRH-II)
(A) and not with the green ¢lter (antibody against GnRH-I) (B).
Massive immunoreactivy is seen in the median eminence that was
reacted with an antiboby against GnRH-II (C), but not with an
antibody against GnRH-I (D). ME, median eminence; 3V, third
ventricle; scale bar, 10 Wm.
Fig. 2. Immunoreactive GnRH-II cells and ¢bers in coronal sections
through the midbrain area of the mature female rat (A^C), of the
hypogonadal mouse (D, E), of a 36-weeks-old infant (F^H), and of
a 60-years-old man (I). In the rat, GnRH-II immunoreactive neu-
rons (arrows) are visualized mainly in the oculomotor nucleus (ON)
of the midbrain (A^C), and to a lesser extent in the red nucleus (R)
(A). GnRH-II immunopositive neurons in the ON (D) and in the
arcuate nucleus (E) of the hypogonadal mouse are seen. Dense ac-
cumulation of GnRH-II immunoreactive neurons are seen in the
periaqueductal region of the human midbrain (F, G). The ON nu-
cleus of the human is not as rich in GnRH-II immunopositive neu-
ronal cells (H, I) as that of the rodents. Immunoreactive GnRH-II
¢bers and cell protuberants (arrowheads) are seen in many of the
GnRH-II immunopositive neurons (C and H), Aq, aqueduct; CG,
central grey; 3V, third ventricle A, U3; B, F, U12; E, U24; C, D,
G, U48; H, U72; H, U120. H, I were stained also by hematoxy-
line to demonstrate nuclei of cells.
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of the hypothalamus (Fig. 3A) and in the median eminence
(Fig. 3C). As expected, these hypothalamic regions of the hpg
mouse did not show any GnRH-I immunoreactivity (Fig. 3B
and D). In the human, GnRH-II immunopositive neurons are
seen in the periaqueductal region of the midbrain (Fig. 2F and
G). In the rat and mouse, GnRH-II positive cells are also
scattered in the periaqueductal region of the midbrain, but
in the human they are much more abundant. On the other
hand, the density of the GnRH-II immunopositive cells in the
human oculomotor nucleus (Fig. 2H and I) is not as impres-
sive as in the rodents. The speci¢city of the signals was tested
by preabsorbing the GnRH-II antiserum with 100 Wg of
GnRH-II for 24 h, or by omitting the GnRH-II antiserum.
In both cases no staining was evident whereas preabsorbtion
with GnRH-I did not a¡ect the staining. When we have re-
placed the GnRH-II antibody by a polyclonal antibody to
vasopressin, staining was found only in the paraventricular
nucleus of the rat hypothalamus.
RT-PCR and Southern hybridization have demonstrated
(Fig. 4) that GnRH-II is expressed in the di¡erent regions
of the human brain stem and especially in the midbrain.
GnRH-II is not expressed in the cerebellum. The results of
this experiment correlate well with our quantitative determi-
nations of GnRH-II in these tissues.
4. Discussion
By using a variety of techniques, we have found an addi-
tional isoform of GnRH, GnRH-II, in the brain of the mouse,
rat and human. GnRH-II was found to be present in neuronal
cells that are localized mainly in the periaqueductal area as
well as in the oculomotor and red nuclei of the midbrain. A
similar distribution of GnRH-II was reported in amphibia,
where this neuropeptide was restricted to the midbrain teg-
mentum [34], and in the musk shrew, one of the most prim-
itive mammals. GnRH-II immunoreactive cells were found in
the periaqueductal region, in the regions of the oculomotor
and red nuclei as well as in the basal hypothalamus median
eminence region of the musk shrew [20].
The strictly conserved structure of the GnRH-II peptide,
from the primitive ¢sh to the human, suggests that this neuro-
peptide possesses vital bioactivities. However, the biological
functions of GnRH-II are practically still unknown. In the
brain stem, GnRH-II may act as a neurotransmitter or as a
neurotrophin and thus a¡ect neuronal growth, di¡erentiation
and functions. In the bullfrog, application of exogenous
GnRH-I has been reported to inhibit a speci¢c voltage-de-
pendent potassium current leading to depolarization of sym-
pathetic neurons and to induction of a late, slow excitatory
postsynaptic potential [35]. More recently it was found that
GnRH-II is at least 1000 times more potent than GnRH-I in
inducing this e¡ect, suggesting it is the endogenous transmit-
ter that mediates the excitatory postsynaptic potential [36,37].
Studies in mammals have indicated a role for GnRH in the
process of sexual di¡erentiation of the brain [38]. Other stud-
ies demonstrated the involvement of GnRH in the induction
of sexual behavior. Thus, GnRH-I that was administered into
the midbrain central grey has been demonstrated to facilitate
sexual behavior [39]. However, the high doses of GnRH-I
(mM range) that were needed to induce this phenomenon
and the discovery of another isoform of GnRH in the mid-
brain raises the possibility that GnRH-II is the physiological
regulator of mating behavior. This hypothesis is strengthened
by the ¢nding that the interaction of female musk shrews with
males induces rapid changes in speci¢c populations of GnRH
immunoreactive cells [40]. A critical examination of the rele-
vant literature projects discrepancies between the reported bi-
ological potency of various GnRH-I analogs in the pituitary
gland as compared to their potency in the brain. Thus, ana-
logs or fragments of GnRH-I that are unable to activate the
pituitary gland could induce sexual behavior, whereas other
GnRH analogs that are potent secretagogues of gonadotro-
pins were unable to induce mating behavior [41,42]. These
observations suggest that the activities of GnRH in the brain
are not mediated by the known GnRH-I receptor, and imply
that the behavioral e¡ects of GnRH in the brain are mediated
by an as yet unknown receptor.
The production of GnRH-II in the hypothalamus of mouse
and human and its presence in the median eminence of the
mouse and in the pituitary stalk of human, demonstrated
herein, imply that in addition to its neurotransmitter roles,
GnRH-II may possess neurohormonal functions at the pitui-
tary gland. Previous studies, however, have demonstrated that
its e⁄cacy in inducing luteinizing hormone release is signi¢-
cantly lower than that of GnRH-I [43]. In view of the lower
concentration of GnRH-II, as compared to GnRH-I, in the
hypothalamus and considering its inferior capability to induce
luteinizing hormone secretion, it seems that the role of
GnRH-II in the hypothalamic pituitary gonadal axis may be
limited to the modulation of GnRH-I activity. This assump-
tion is supported by the fact that the presence of GnRH-II in
the brain of the hypogonadal mouse (Fig. 2D and E, Fig. 3A
and C) is not su⁄cient to cause normal gonadal development.
Alternatively, GnRH-II may activate its intrinsic pituitary re-
ceptor and be responsible for the regulation of other pituitary
functions.
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Fig. 4. A: Southern blot hybridization of ampli¢ed GnRH-II
cDNA fragments. Ampli¢ed GnRH-II cDNA fragments from brain
stem structures and cerebellum of human brain were hybridized to a
human GnRH-II 32P labeled oligonucleotide probe. Lanes: 1, mid-
brain; 2, pons; 3, cerebellum; 4, medulla oblongata. B: Parallel am-
pli¢cation of the ribosomal protein S-14 cDNA, derived from the
same experimental groups as of A, after 1.5% agarose gel electro-
phoresis and ethidium bromide staining.
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